Issues of Optimization of Methotrexate Therapy in Patients With Rheumatoid Arthritis

Гриднева, Г. И.; Муравьев, Ю. В.; Лучихина, Е. Л.; Демидова, Н. В.; Каратеев, Д. Е.

doi:10.14412/1995-4484-2017-41-47

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Для достижения контроля заболевания в настоящее время разработано большое количество синтетических и биологических БПВП. Среди синтетических БПВП неизменным лидером является метотрексат (или его подкожная форма методжект -МТД) с уже доказанной клинической эффективностью [2,3,7,10]. Появление биологических БПВП коренным образом изменило представление о лечении РА -«treat to target».…”

Section: Doiunclassified

Эндотелиотропные Эффекты Методжекта И Ритуксимаба У Больных Ревматоидным Артритом И Гипертонической Болезнью

Гришина¹,

университет²,

Покровская³

et al. 2018

Innova

View full text Add to dashboard Cite

Section: Doiunclassified

Эндотелиотропные Эффекты Методжекта И Ритуксимаба У Больных Ревматоидным Артритом И Гипертонической Болезнью

Гришина¹,

университет²,

Покровская³

et al. 2018

Innova

View full text Add to dashboard Cite

“…Ожирение, важнейший компонент метаболического синдрома, наблюдается у 63-68% больных РА и ассоциируется с большей активностью заболевания и недостаточной эффективностью противовоспалительной терапии [13][14][15]. Адипоциты и макрофаги жировой ткани способны продуцировать такие цитокины, как ФНОα и интерлейкин 6, а следовательно, участвовать в развитии и поддержании воспаления.…”

Section: результатыunclassified

Type 2 Diabetes Mellitus Risk Assessment Using Findrisc in Patients With Rheumatoid Arthritis

Кондратьева¹,

Попкова²,

Nasonov³

2017

rsp

View full text Add to dashboard Cite

show abstract

The use of subcutaneous methotrexate from various manufacturers in real clinical practice: a comparative study

et al. 2019

View full text Add to dashboard Cite

Background: Methotrexate is the main synthetic disease-modifying antirheumatic drug for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other immunoinflammatory conditions. In the recent years, the subcutaneous form of methotrexate (SC MTX), particularly as ready-to-use syringes, has been increasingly used worldwide. Currently, several generics of SC MTX from different manufacturers are available. In literature we could not find any publications on the comparison of SC MTX generics.Aim: To evaluate the possibility to effectively use various SC MTXs for the treatment of RA and PsA in real clinical practice. Materials and methods: Patients older than 18 years old with a diagnosis of RA by ACR 1987 or ACR / EULAR 2010 criteria or diagnosis of PsA by CASPAR criteria with indications for SC MTX were included in this open-label 6-month observational study “Therapy of Rheumatoid Arthritis with Methotrexate in the Subcutaneous Form in Clinical Practice (TRAMPLIN)”. TRAMPLIN included two study periods: 1) a retrospective study of the safety of SC MTX from various manufacturers in clinical practice, according to patients' medical records; 632 patients (67.2% female, 32.8% male) on SC MTX were identified, and the number of adverse reactions recorded in the documentation (spontaneous reports) was determined; 2) a prospective study of the treatment duration and the reasons for the withdrawal of SC MTX from different manufacturers, which included 69 patients with RA and PsA. SC MTXs from three manufacturers were used in this study, namely Metoject (Medac GmbH, Germany); Métortrites (S.C. Rompharm Company S.R.L., Romania); Methotrexat Ebewe (Sandoz Pharmaceuticals D.D., Slovenia).Results: In the retrospective part of the study very few adverse events (AEs) were registered, which were related to SC MTX in the physician's opinion (41 patients, or 6.5%). Their incidence was higher in methotrexate-naïve patients. In the prospective part of the study at 3 months after the start of SC MTX therapy, 25 patients (36.2%) changed the treatment regimen (switched between the study drugs or to oral methotrexate). The main reasons for switching (20.3%) were “non-medical” events in the outpatients. AEs ranked second as a reason for the drug withdrawal (14.5%), irrespective of the manufacturer. At 6 month of the study, 38% patients were treated with Metoject, 30% with Methotrexat Ebewe, 28% with Métortrites, and 4% of patients switched to oral methotrexate.Conclusion: This first Russian study of SC MTX generics from three different manufacturers confirmed a good SC MTX safety profile in a large clinical sample and showed good retention rates for therapy: by the end of the observation, 96% of the patients with available follow-up data remained on SC MTX. All three SC MTXs from different manufacturers were compatible in terms of safety, tolerability, and drug survival.

show abstract

Issues of Optimization of Methotrexate Therapy in Patients With Rheumatoid Arthritis

Cited by 6 publications

References 19 publications

Эндотелиотропные Эффекты Методжекта И Ритуксимаба У Больных Ревматоидным Артритом И Гипертонической Болезнью

Эндотелиотропные Эффекты Методжекта И Ритуксимаба У Больных Ревматоидным Артритом И Гипертонической Болезнью

Type 2 Diabetes Mellitus Risk Assessment Using Findrisc in Patients With Rheumatoid Arthritis

The use of subcutaneous methotrexate from various manufacturers in real clinical practice: a comparative study

Contact Info

Product

Resources

About